SCHEMBL2359484

SCHEMBL2359484

O=C1CCCc2c1[nH]c1c(Cl)c(Cl)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
HSD17B10 Q99714 5/20 0.56
LMNA P02545 5/20 0.52
GAA P10253 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 6/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.46
MAPK1 P28482 1/20 0.46
AR P10275 1/20 0.45
DYRK1A Q13627 1/20 0.39
BRD4 O60885 4/20 0.39
POLB P06746 1/20 0.38
HTT P42858 1/20 0.37
PTK2B Q14289 1/20 0.37
BRDT Q58F21 1/20 0.36
CREBBP Q92793 1/20 0.36
CECR2 Q9BXF3 1/20 0.36
BRD9 Q9H8M2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360276 0.78 HTT (0.60) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL2360274 0.75 KDM4E (0.60) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL2359337 0.75 KDM4E (0.56) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL2358941 0.73 ALDH1A1 (0.51) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL14701100 0.73 ALDH1A1 (0.58) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL2359682 0.72 ALDH1A1 (0.47) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL1654097 0.72 KDM4E (0.68) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL2315927 0.72 KDM4E (0.68) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL22529407 0.72 KDM4E (0.52) KDM4EHSD17B10LMNAGAAMEN1
SCHEMBL4156318 0.72 KDM4E (1.00) KDM4EHSD17B10LMNAGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
WO-2013139929-A1 NOVEL MEANS AND METHODS FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM, METABOLIC AND CARDIAC DISEASES AND AGING LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2013-09-26 WO disclosed
WO-2013139929-A1 NOVEL MEANS AND METHODS FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM, METABOLIC AND CARDIAC DISEASES AND AGING LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2013-09-26 WO disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
EP-2531029-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2012-12-12 EP disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121285-A1 Selective androgen receptor modulators AR, SHBG, FSHR KDM4E 1228/4885HSD17B10 236/4885LMNA 1424/4885
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, FSHR KDM4E 1235/4885HSD17B10 239/4885LMNA 1414/4885
US-20130041007-A1 Selective Androgen Receptor Modulators AR, SHBG, GPR119 KDM4E 1925/4885HSD17B10 273/4885LMNA 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.